| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1022538531 |
| P356 | DOI | 10.1186/1757-2215-3-8 |
| P932 | PMC publication ID | 2856581 |
| P698 | PubMed publication ID | 20350313 |
| P5875 | ResearchGate publication ID | 42638204 |
| P2093 | author name string | Joseph P Connor | |
| Manish S Patankar | |||
| Nick Claussen | |||
| Arvinder K Kapur | |||
| Jennifer Aa Gubbels | |||
| P2860 | cites work | TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator | Q24292670 |
| Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion | Q24301956 | ||
| Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies | Q24531993 | ||
| Mesothelin targeted cancer immunotherapy | Q24656242 | ||
| A binding domain on mesothelin for CA125/MUC16 | Q24658397 | ||
| Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors | Q24673454 | ||
| Cancer statistics, 2008 | Q27860585 | ||
| Letal, A tumor-associated NKG2D immunoreceptor ligand, induces activation and expansion of effector immune cells | Q28204913 | ||
| Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125) | Q80580929 | ||
| Tumor-derived soluble MICs impair CD3(+)CD56(+) NKT-like cell cytotoxicity in cancer patients | Q81728290 | ||
| Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients | Q81753024 | ||
| Mechanisms of metastasis | Q83008844 | ||
| The clonal evolution of metastases from primary serous epithelial ovarian cancers | Q46611624 | ||
| The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. | Q46864787 | ||
| The CA 125 gene: a newly discovered extension of the glycosylated N-terminal domain doubles the size of this extracellular superstructure | Q47178130 | ||
| Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis | Q47347848 | ||
| Interleukin-6 fused to an anti-idiotype antibody in a vaccine increases the specific humoral immune response against CA125+ (MUC-16) ovarian cancer. | Q47826317 | ||
| Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. | Q50512108 | ||
| Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk. | Q50950163 | ||
| Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. | Q51842388 | ||
| Factors affecting the association of oral contraceptives and ovarian cancer. | Q52875333 | ||
| Intraperitoneal cisplatin and paclitaxel in ovarian cancer. | Q53263238 | ||
| Ascites from epithelial ovarian cancer contain high levels of functional decoy receptor 3 (DcR3) and is associated with platinum resistance. | Q53458585 | ||
| Isolation and characterization of human natural killer cell subsets. | Q53481399 | ||
| Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. | Q55042194 | ||
| Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation | Q59055770 | ||
| Clinical and Pathological Features of Ovarian Cancer in Women with Germ-Line Mutations ofBRCA1 | Q63183299 | ||
| Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix | Q63446426 | ||
| Monitoring human ovarian carcinoma with a combination of CA 125, CA 19-9, and carcinoembryonic antigen | Q63446427 | ||
| Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer | Q68090336 | ||
| Elevated serum concentrations of CA-125 in patients with advanced endometriosis | Q68723345 | ||
| CA-125 in patients with endometriosis | Q68963127 | ||
| Extraovarian peritoneal serous papillary carcinoma. A clinicopathologic study of 31 cases | Q69626773 | ||
| Lymphocyte cytotoxicity in the peritoneal cavity and blood of patients with ovarian cancer | Q70656081 | ||
| Determinants of ovarian cancer risk. I. Reproductive experiences and family history | Q70915474 | ||
| Reciprocal Interactions between Human Ovarian Surface Epithelial Cells and Adjacent Extracellular Matrix | Q71655942 | ||
| Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas | Q72722122 | ||
| CA125 antigen levels in obstetric and gynecologic patients | Q72748884 | ||
| Clinical course of ovarian cancer patients under repeated stimulation of HAMA using MAb OC125 and B43.13 | Q72754437 | ||
| CA-125 in peritoneal fluid from patients with nonmalignant gynecologic disorders | Q72819142 | ||
| Serum and tissue measurements of CA72-4 in ovarian cancer patients | Q72947691 | ||
| Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13--evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo | Q74260446 | ||
| Prognostic factors in ovarian cancer | Q74673849 | ||
| Focus on epithelial ovarian cancer | Q75353680 | ||
| Distribution pattern and risk factors of pelvic and para-aortic lymph node metastasis in epithelial ovarian carcinoma | Q77371908 | ||
| Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer | Q78969303 | ||
| The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR | Q79149161 | ||
| Use of CA125 fluctuation during the menstrual cycle as a tool in the clinical diagnosis of endometriosis; a preliminary report | Q80418026 | ||
| Ovarian surface epithelium: biology, endocrinology, and pathology | Q28211321 | ||
| Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2 | Q28212276 | ||
| Ovarian carcinoma expresses the NKG2D ligand Letal and promotes the survival and expansion of CD28- antitumor T cells | Q28250971 | ||
| SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other | Q28283527 | ||
| Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer | Q28293019 | ||
| The cell of origin of ovarian epithelial tumours | Q28302089 | ||
| Molecular pathways regulating EGF-induced epithelio-mesenchymal transition in human ovarian surface epithelium | Q29030494 | ||
| The distribution of secondary growths in cancer of the breast. 1889 | Q29614314 | ||
| Tumor metastasis: mechanistic insights and clinical challenges | Q29617676 | ||
| Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer | Q29620068 | ||
| Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. | Q30670385 | ||
| Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). | Q30781823 | ||
| A candidate precursor to serous carcinoma that originates in the distal fallopian tube. | Q33264156 | ||
| Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G | Q33335882 | ||
| The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: does the emperor have no clothes? | Q33537711 | ||
| Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study | Q33574039 | ||
| MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells | Q33638962 | ||
| Review: gonadotropins and development of ovarian cancer | Q33764649 | ||
| Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy | Q33828838 | ||
| Mesothelin is not required for normal mouse development or reproduction | Q33895649 | ||
| Ovarian cancer: epidemiology, biology, and prognostic factors | Q33959805 | ||
| Incessant ovulation--a factor in ovarian neoplasia? | Q34051579 | ||
| The CA 125 gene: an extracellular superstructure dominated by repeat sequences | Q34109036 | ||
| Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. | Q34111770 | ||
| Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene | Q34121019 | ||
| The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. | Q34211073 | ||
| A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer | Q34254918 | ||
| Potential markers that complement expression of CA125 in epithelial ovarian cancer | Q34439240 | ||
| EGF/ErbB receptor family in ovarian cancer | Q34483792 | ||
| Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer. | Q34483798 | ||
| Prevention and early detection of ovarian cancer: mission impossible? | Q34575612 | ||
| A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations | Q34761925 | ||
| Risk factors for a serous cancer precursor ("p53 signature") in women with inherited BRCA mutations | Q34811314 | ||
| Status of Tumor Markers in Ovarian Cancer Screening | Q35125949 | ||
| Ovarian cancer: strategies for overcoming resistance to chemotherapy | Q35166813 | ||
| Modulation of TcR/CD3-zeta chain expression by a circulating factor derived from ovarian cancer patients | Q36622390 | ||
| Mechanisms of transcoelomic metastasis in ovarian cancer. | Q36643128 | ||
| Epithelial-mesenchymal interconversions in normal ovarian surface epithelium and ovarian carcinomas: an exception to the norm. | Q36914343 | ||
| Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction | Q36924865 | ||
| Molecular pathogenesis and therapeutic targets in epithelial ovarian cancer. | Q36945763 | ||
| Ascites specific inhibition of CD1d-mediated activation of natural killer T cells. | Q37177987 | ||
| NKG2D ligands in tumor immunity | Q37287179 | ||
| Tumor invasion and metastasis: an imbalance of positive and negative regulation. | Q37289935 | ||
| Combining a symptoms index with CA 125 to improve detection of ovarian cancer. | Q37324647 | ||
| The temporal stability of the Symptom Index among women at high-risk for ovarian cancer. | Q37329916 | ||
| Epidemiology of ovarian cancer | Q37358065 | ||
| Multicellular spheroids in ovarian cancer metastases: Biology and pathology. | Q37366009 | ||
| Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors | Q37412304 | ||
| Decoy receptor 3 overexpression and immunologic tolerance in hepatocellular carcinoma (HCC) development | Q38358028 | ||
| Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer | Q39741066 | ||
| Development of an ovarian cancer symptom index: possibilities for earlier detection. | Q39777813 | ||
| Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer | Q39796555 | ||
| Priming and activation of human ovarian and breast cancer-specific CD8+ T cells by polyvalent Listeria monocytogenes-based vaccines | Q39799815 | ||
| Memory and cellular immunity induced by a DNA vaccine encoding self antigen TPD52 administered with soluble GM-CSF. | Q39890891 | ||
| Establishment of an ovarian metastasis model and possible involvement of E-cadherin down-regulation in the metastasis | Q39915235 | ||
| Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. | Q39959127 | ||
| Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer | Q40019095 | ||
| Correlation between expression of DcR3 on tumor cells and sensitivity to FasL. | Q40029680 | ||
| Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts | Q40041128 | ||
| Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. | Q40111238 | ||
| Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. | Q40469093 | ||
| Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis | Q40552203 | ||
| Ovarian carcinoma cells inhibit T cell proliferation: suppression of IL-2 receptor beta and gamma expression and their JAK-STAT signaling pathway | Q40596065 | ||
| Development of a syngeneic mouse model for events related to ovarian cancer | Q40888613 | ||
| Immunotherapy of human ovarian carcinoma with OvaRex MAb-B43.13 in a human-PBL-SCID/BG mouse model | Q40959437 | ||
| Spontaneous transformation of rat ovarian surface epithelial cells results in well to poorly differentiated tumors with a parallel range of cytogenetic complexity | Q41033264 | ||
| Pathology of ovarian cancer precursors | Q41070262 | ||
| Spontaneous transformation of rat ovarian surface epithelial cells: association with cytogenetic changes and implications of repeated ovulation in the etiology of ovarian cancer | Q41114970 | ||
| The E-cadherin/catenin complex in invasion and metastasis | Q41117074 | ||
| Ovulation-induced DNA damage in ovarian surface epithelial cells of ewes: prospective regulatory mechanisms of repair/survival and apoptosis | Q43774838 | ||
| Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. | Q43779560 | ||
| Papillary serous carcinoma of the peritoneum | Q44099816 | ||
| Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial | Q44426842 | ||
| Effects of epidermal growth factor/hydrocortisone on the growth and differentiation of human ovarian surface epithelium | Q44878671 | ||
| Characterization of the CA 125 antigen associated with human epithelial ovarian carcinomas. | Q44986187 | ||
| Factors affecting the completion of intraperitoneal chemotherapy in women with ovarian cancer | Q45111172 | ||
| Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. | Q45728676 | ||
| Tissue expression of CA 125 in benign and malignant lesions of ovary and fallopian tube: a comparison with CA 19-9 and CEA. | Q45789637 | ||
| Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. | Q46016693 | ||
| Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models | Q46407253 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | obstetrics and gynaecology | Q80015 |
| ovarian cancer | Q172341 | ||
| P304 | page(s) | 8 | |
| P577 | publication date | 2010-01-01 | |
| P1433 | published in | Journal of Ovarian Research | Q27721898 |
| P1476 | title | The detection, treatment, and biology of epithelial ovarian cancer | |
| P478 | volume | 3 |
| Q98576258 | An enzymatic toolkit for selective proteolysis, detection, and visualization of mucin-domain glycoproteins |
| Q54990434 | Clinical observation and therapeutic evaluation of intravenous pump of recombinant human endostatin combined with TP regimen in treating patients with advanced ovarian cancer. |
| Q36244004 | Comparative study of various subpopulations of cytotoxic cells in blood and ascites from patients with ovarian carcinoma. |
| Q38819836 | Differential expression of ligands for NKG2D and DNAM-1 receptors by epithelial ovarian cancer-derived exosomes and its influence on NK cell cytotoxicity |
| Q39165116 | Effect of siRNA targeting MTA1 on metastasis malignant phenotype of ovarian cancer A2780 cells |
| Q36261318 | FBXW12, a novel F box protein-encoding gene, is deleted or methylated in some cases of epithelial ovarian cancer |
| Q47192007 | Fluorescence-guided surgery for cancer patients: a proof of concept study on human xenografts in mice and spontaneous tumors in pets |
| Q48269600 | Genome-wide profiling of the PIWI-interacting RNA-mRNA regulatory networks in epithelial ovarian cancers. |
| Q35001563 | HN125: A Novel Immunoadhesin Targeting MUC16 with Potential for Cancer Therapy |
| Q34738849 | Kallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous ovarian cancer subtypes |
| Q34285363 | Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy. |
| Q37822160 | Novel nanotechnology approaches to diagnosis and therapy of ovarian cancer |
| Q34442653 | Optical biomarkers of serous and mucinous human ovarian tumor assessed with nonlinear optics microscopies |
| Q34150097 | Ovarian cancer biomarkers for molecular biosensors and translational medicine |
| Q40194144 | Over-expression of nuclear NF-κB1 and c-Rel correlates with chemoresistance and prognosis of serous epithelial ovarian cancer |
| Q36524069 | Overexpression of S100A14 in human serous ovarian carcinoma |
| Q35675494 | Paclitaxel improved anti-L1CAM lutetium-177 radioimmunotherapy in an ovarian cancer xenograft model |
| Q27315878 | Protein kinase A activity and anchoring are required for ovarian cancer cell migration and invasion |
| Q37997512 | Recent advances in drug delivery strategies for treatment of ovarian cancer |
| Q28540458 | Retracted: The Inhibitory Effect of Doxycycline on Cisplatin-Sensitive and -Resistant Epithelial Ovarian Cancer |
| Q36880907 | Safe and targeted anticancer therapy for ovarian cancer using a novel class of curcumin analogs |
| Q36642148 | Synergistic cytotoxic effect of sulindac and pyrrolidine dithiocarbamate against ovarian cancer cells |
| Q58726271 | The Impact of Mesothelin in the Ovarian Cancer Tumor Microenvironment |
| Q38650275 | The Inhibitory Effect of Ginger Extract on Ovarian Cancer Cell Line; Application of Systems Biology |
| Q35077893 | The immunomodulating roles of glycoproteins in epithelial ovarian cancer |
| Q48260059 | Trans10,cis12 conjugated linoleic acid inhibits proliferation and migration of ovarian cancer cells by inducing ER stress, autophagy, and modulation of Src. |
| Q36431063 | Triptolide inhibits ovarian cancer cell invasion by repression of matrix metalloproteinase 7 and 19 and upregulation of E-cadherin |
Search more.